Lenalidomide's drug use for children and the elderly
Usage for children of Lenalidomide
There is no experience in medicine for children and adolescents. Therefore, this product should not be used in patients between 0 and 17 years old.
Usage for the elderly
In the clinical trial of the treatment of multiple myeloma, the highest age of the patient was 86 years.
Among the 703 patients with multiple myeloma treated by this product in the study of MM-009 and MM-010, 45% of the patients were older than 65 years old and 12% were older than 75 years old. There was no significant difference in the proportion of patients who were 65 years older between lenalidomide/ dexamethasone group and placebo/dexamethasone group. Of the 353 patients who received lenalidomide /dexamethasone, 46 percent were older than 65. In both studies found that receiving the drug lenalidomide/dexamethasone, the patients over the age of 65 were more likely to have deep venous thrombosis, pulmonary embolism, atrial fibrillation, and renal failure than those with no more than 65 years of age, but no difference in efficacy was observed between the two. Since elderly patients are more likely to suffer from kidney failure, they should be cautious and monitor their renal function when choosing a dose.
Adverse reaction of Lenalidomide
The most common adverse reaction to lenalidomide is thrombocytopenia (21. 5%) and neutropenia (42.2%). Other more common side effects include diarrhea, itching, rash, fatigue, constipation, nausea, nasopharyngitis, joint pain, fever, pain, peripheral edema, cough, dizziness, headache, muscle pain, cramps, breathing difficulties and pharyngitis.